License Royalties. 3.1 In partial consideration for the license granted by STANFORD to RIGEL under Section 2.1, RIGEL agrees to pay to STANFORD the following:
License Royalties. 5.2.1 In consideration of the rights and licence granted to Acorda to the Elan Patent Rights by virtue of the SCI Agreement, Acorda has paid to Elan $5,000,000 (five million United States Dollars); and
License Royalties. 1. In consideration of the rights and license granted to IOMED to the DDS IONTOPHORETIC PATENT RIGHTS by virtue of this Agreement, IOMED shall pay to DDS, the sum of **** United States Dollars **** in cash by wire transfer due upon execution of this Agreement and payable within two business days of the EFFECTIVE DATE.
License Royalties. 1. In consideration of the rights and license granted to IOMED to the ELAN IONTOPHORETIC PATENT RIGHTS by virtue of this Agreement, IOMED shall pay to ELAN, the sum of **** United States Dollars **** in cash by wire transfer due upon execution of this Agreement and payable within two business days of the EFFECTIVE DATE.
License Royalties. 7.1.1 In consideration of the license of the ELAN PATENTS granted to GEMINI under this Agreement, GEMINI shall pay to ELAN
License Royalties. 9.01 The license granted in Paragraph 8.01 shall be royalty-bearing, based on the following two-tier royalty structure, with the exact royalties to be negotiated for each generation of LAD commercialized by or on behalf of Grace at the time the relevant Cedars-Sinai LAD Technology is available for use. A lower royalty shall be paid for the use of Cedars-Sinai know-how only (that is, if no patents are included in the licensed Cedars-Sinai LAD Technology). A higher royalty would be paid in the event the commercial LAD is covered by one or more Licensed Patents. No double royalty would be paid. It is acknowledged by the parties that the presence or absence of patent coverage for the relevant Cedars-Sinai LAD Technology may vary by country and that the appropriate royalty from the two-tier structure will be determined on a country-by-country basis.
License Royalties. In consideration for Licensor’s granting of the license granted under Section 2.1, Licensee shall pay Licensor a perpetual license royalty as follows:
License Royalties. As part of the consideration for the rights granted by Baxter to Licensee, Licensee shall pay, or cause to be paid to Baxter, the following royalties based on Net Sales of Licensed Products:
License Royalties. In consideration for the license (including sublicense) rights that Licensor grants to Licensee under Section 2, Licensee shall issue to Licensor 9,789,000 shares of its common stock and 5-year warrants to purchase 1,808,307 shares of its common stock at an exercise price of $0.87 per share, and shall pay the Licensor One Hundred Thousand Dollars ($100,000) (the “License Royalties”).
License Royalties. (a) Hologic hereby grants, and shall cause any Hologic Affiliate that owns or has the right to license any Hologic Patent to hereby grant, to Conceptus, Conceptus Affiliates, Conceptus Contractors and Conceptus Customers an irrevocable, world-wide, royalty-bearing, nonsublicenseable, non-transferable (except in accordance with Section 8.2) and non-exclusive license under the Hologic Patents in the PBC Field: (i) to make, have made, use, sell, offer to sell, practice, lease, keep, import, have imported, export, have exported, distribute (including through multiple channels of distribution), commercially exploit or otherwise dispose of Conceptus Products and Services; and (ii) to practice any method or process claimed in the Hologic Patents for purposes of effectuating the license granted in clause (i) of this Section 4.2(a).
